Syndax Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 78 to 84.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an RS Rating of over 80 as they launch their biggest price moves.
While now is not an ideal time to buy shares, see if the stock is able to establish and enter a buy zone in heavy volume.
The company showed 0% EPS growth in the latest quarterly report. Sales rose 985%.
Syndax Pharmaceuticals earns the No. 118 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
